Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Go back to Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis| Regeneron (NASDAQ: REGN) | Delayed: 840.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $840.84 | 52 Week High | $592.36 | |||
| Open | $840.84 | 52 Week Low | $325.35 | |||
| Day High | $840.84 | P/E | 220.69 | |||
| Day Low | $840.84 | EPS | $3.81 | |||
| Volume | 758 | |||||
| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 58.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.20 | 52 Week High | $35.13 | |||
| Open | $58.20 | 52 Week Low | $28.10 | |||
| Day High | $58.20 | P/E | N/A | |||
| Day Low | $58.20 | EPS | $0.00 | |||
| Volume | 871 | |||||
